Press coverage about Illumina (NASDAQ:ILMN) has been trending somewhat positive on Sunday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Illumina earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned media headlines about the life sciences company an impact score of 46.3637128407283 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:
- ILLUMINA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the … (businesswire.com)
- ILLUMINA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Illumina, Inc. – ILMN (markets.financialcontent.com)
- Illumina (ILMN) Coverage Initiated by Analysts at Evercore ISI (americanbankingnews.com)
- Global Pyrosequencing Market 2018 – Genomnia, Illumina, Macrogen, Microsynth AG (theanalystfinancial.com)
- Piper Jaffray Reiterates Buy Rating for Illumina (ILMN) (americanbankingnews.com)
Shares of ILMN stock traded up $1.43 during trading on Friday, hitting $236.42. 719,888 shares of the stock traded hands, compared to its average volume of 759,277. The firm has a market cap of $34,753.74, a PE ratio of 59.11, a PEG ratio of 3.12 and a beta of 0.93. The company has a debt-to-equity ratio of 0.43, a quick ratio of 3.55 and a current ratio of 3.99. Illumina has a 52-week low of $167.16 and a 52-week high of $256.64.
Several equities research analysts recently issued reports on ILMN shares. Wells Fargo reiterated a “positive” rating and issued a $260.00 price objective (up from $250.00) on shares of Illumina in a report on Tuesday, January 9th. BidaskClub upgraded Illumina from a “hold” rating to a “buy” rating in a report on Saturday, March 10th. BTIG Research started coverage on Illumina in a report on Friday, January 5th. They issued a “neutral” rating on the stock. Piper Jaffray lifted their price objective on Illumina to $274.00 and gave the stock an “overweight” rating in a report on Thursday, January 4th. Finally, Evercore ISI started coverage on Illumina in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $250.00 price objective on the stock. One analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $241.39.
In other news, Director Robert S. Epstein sold 1,250 shares of Illumina stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $244.18, for a total transaction of $305,225.00. Following the sale, the director now owns 8,588 shares of the company’s stock, valued at approximately $2,097,017.84. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $223.40, for a total transaction of $4,468,000.00. Following the sale, the director now directly owns 463,436 shares in the company, valued at approximately $103,531,602.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,637 shares of company stock worth $11,720,040. Corporate insiders own 0.89% of the company’s stock.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.